AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha- synuclein programs targeting neurodegenerative diseases

AFFiRiS AG announced that AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS’ anti-alpha-synuclein programs targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS´ AFFITOME® technology.

The all-stock acquisition is valued at USD 58.7 million. Under the terms of the agreement, ACoImmune is acquiring all of AFFiRiS´ assets and underlying intellectual property related to active vaccine candidates targeting alpha-synuclein and USD 5 million in cash for 7.1 million shares of AC Immune common stock based on a price of USD 8.26 per common share.

Read more